ACT Announces Completion of Higher-Dosage Cohort in Both U.S. Clinical Trials

  ACT Announces Completion of Higher-Dosage Cohort in Both U.S. Clinical
  Trials

   Three Patients with Forms of Macular Degeneration Injected with 100,000
        hESC-Derived RPE Cells, Successfully Completing Second Cohort

Business Wire

MARLBOROUGH, Mass. -- November 28, 2012

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader
in the field of regenerative medicine, today announced treatment of three
additional patients in the company’s two U.S. trials using retinal pigment
epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The
fifth and sixth patients in the company’s Phase I/II clinical trial for dry
age-related macular degeneration (dry AMD) were treated, completing the second
patient cohort. The fifth patient was treated at Massachusetts Eye and Ear
Infirmary, a Harvard Medical School affiliate, by a surgical team led by Dean
Eliott, M.D., afull-time retina surgeon, scientist and associate director of
the Retina Service at Mass. Eye and Ear. Additionally, the sixth patient in
the company’s clinical trial for Stargardt’s Macular Dystrophy (SMD) was
treated, also completing that second cohort. All three patients were injected
with 100,000 hESC-derived RPE cells and are recovering uneventfully.

“We could not be more pleased to have now completed the second, higher-dose
patient cohort in both of our U.S. clinical trials,” commented Gary Rabin,
chairman and CEO of ACT. “We continue to be encouraged by our progress in all
three of our clinical trials and are eagerly anticipating proceeding to the
third, 150,000-cell patient cohort.”

The company is conducting a total of three clinical trials in the U.S. and
Europe. Each trial will enroll a total of 12 patients, with cohorts of three
patients in an ascending dosage format. These trials are prospective,
open-label studies designed to determine the safety and tolerability of
hESC-derived RPE cells following sub-retinal transplantation into patients
with dry AMD or SMD at 12 months, the study’s primary endpoint. Preliminary
results from the two U.S. trials were reported in The Lancet earlier this
year.

“Completing the higher-cell dosage in both our U.S. trials is an important
milestone in our clinical programs,” said Robert Lanza, M.D., ACT’s chief
scientific officer. “We are now halfway through both U.S. trials, and look
forward to treating the remaining two patient cohorts in the coming year.”

Added Dr. Eliott, “Dry AMD affects upwards of 30 million people worldwide.
Moreover, it has no approved drug treatment available to date. ACT’s
hESC-derived RPE cells could address this considerable unmet need and also
point the way towards treatments of other forms of macular degeneration. We
are pleased to be a part of this important clinical trial.”

Further information about patient eligibility for ACT’s dry AMD study and the
concurrent studies in the U.S. and the E.U. for SMD is available
atwww.clinicaltrials.govwith the following Identifiers: NCT01344993 (dry
AMD), NCT01345006 (U.S. SMD) and NCT01469832 (E.U. SMD).

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
www.advancedcell.com.

About Mass. Eye and Ear

Mass. Eye and Ear clinicians and scientists are driven by a mission to find
cures for blindness, deafness and diseases of the head and neck. After uniting
with Schepens Eye Research Institute in 2011, Mass. Eye and Ear in Boston
became the world's largest vision and hearing research center, offering hope
and healing to patients everywhere through discovery and innovation. Mass. Eye
and Ear is a Harvard Medical School teaching hospital and trains future
medical leaders in ophthalmology and otolaryngology, through residency as well
as clinical and research fellowships. Internationally acclaimed since its
founding in 1824, Mass. Eye and Ear employs full-time, board-certified
physicians who offer high-quality and affordable specialty care that ranges
from the routine to the very complex. U.S. News & World Report’s “Best
Hospitals Survey” has consistently ranked the Mass. Eye and Ear Departments of
Otolaryngology and Ophthalmology as top five in the nation. Mass. Eye and Ear
is home to the Ocular Genomics Institute which aims to translate the promise
of personalized genomic medicine into clinical care for ophthalmic disorders.
For more information, visit MassEyeAndEar.org.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292